Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Correction: Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection.

Kijak GH, Sanders-Buell E, Chenine AL, Eller MA, Goonetilleke N, Thomas R, Leviyang S, Harbolick EA, Bose M, Pham P, Oropeza C, Poltavee K, O'Sullivan AM, Billings E, Merbah M, Costanzo MC, Warren JA, Slike B, Li H, Peachman KK, Fischer W, Gao F, Cicala C, Arthos J, Eller LA, O'Connell RJ, Sinei S, Maganga L, Kibuuka H, Nitayaphan S, Rao M, Marovich MA, Krebs SJ, Rolland M, Korber BT, Shaw GM, Michael NL, Robb ML, Tovanabutra S, Kim JH.

PLoS Pathog. 2017 Sep 14;13(9):e1006620. doi: 10.1371/journal.ppat.1006620. eCollection 2017 Sep.

2.

Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection.

Kijak GH, Sanders-Buell E, Chenine AL, Eller MA, Goonetilleke N, Thomas R, Leviyang S, Harbolick EA, Bose M, Pham P, Oropeza C, Poltavee K, O'Sullivan AM, Billings E, Merbah M, Costanzo MC, Warren JA, Slike B, Li H, Peachman KK, Fischer W, Gao F, Cicala C, Arthos J, Eller LA, O'Connell RJ, Sinei S, Maganga L, Kibuuka H, Nitayaphan S, Rao M, Marovich MA, Krebs SJ, Rolland M, Korber BT, Shaw GM, Michael NL, Robb ML, Tovanabutra S, Kim JH.

PLoS Pathog. 2017 Jul 31;13(7):e1006510. doi: 10.1371/journal.ppat.1006510. eCollection 2017 Jul. Erratum in: PLoS Pathog. 2017 Sep 14;13(9):e1006620.

3.

Pox-Protein Public Private Partnership program and upcoming HIV vaccine efficacy trials.

Russell ND, Marovich MA.

Curr Opin HIV AIDS. 2016 Nov;11(6):614-619. Review.

PMID:
27636503
4.

Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV-infected individuals.

Krebs SJ, Slike BM, Sithinamsuwan P, Allen IE, Chalermchai T, Tipsuk S, Phanuphak N, Jagodzinski L, Kim JH, Ananworanich J, Marovich MA, Valcour VG; SEARCH 011 study team.

AIDS. 2016 Jun 19;30(10):1533-42. doi: 10.1097/QAD.0000000000001096.

5.

Expansion of Inefficient HIV-Specific CD8 T Cells during Acute Infection.

Eller MA, Goonetilleke N, Tassaneetrithep B, Eller LA, Costanzo MC, Johnson S, Betts MR, Krebs SJ, Slike BM, Nitayaphan S, Rono K, Tovanabutra S, Maganga L, Kibuuka H, Jagodzinski L, Peel S, Rolland M, Marovich MA, Kim JH, Michael NL, Robb ML, Streeck H.

J Virol. 2016 Mar 28;90(8):4005-4016. doi: 10.1128/JVI.02785-15. Print 2016 Apr.

6.

The Immunology of a Healing Response in Cutaneous Leishmaniasis Treated with Localized Heat or Systemic Antimonial Therapy.

Lakhal-Naouar I, Slike BM, Aronson NE, Marovich MA.

PLoS Negl Trop Dis. 2015 Oct 20;9(10):e0004178. doi: 10.1371/journal.pntd.0004178. eCollection 2015.

7.

Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.

Wieczorek L, Krebs SJ, Kalyanaraman V, Whitney S, Tovanabutra S, Moscoso CG, Sanders-Buell E, Williams C, Slike B, Molnar S, Dussupt V, Alam SM, Chenine AL, Tong T, Hill EL, Liao HX, Hoelscher M, Maboko L, Zolla-Pazner S, Haynes BF, Pensiero M, McCutchan F, Malek-Salehi S, Cheng RH, Robb ML, VanCott T, Michael NL, Marovich MA, Alving CR, Matyas GR, Rao M, Polonis VR.

J Virol. 2015 Aug;89(15):7478-93. doi: 10.1128/JVI.00412-15. Epub 2015 May 13.

8.

Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults.

Joachim A, Nilsson C, Aboud S, Bakari M, Lyamuya EF, Robb ML, Marovich MA, Earl P, Moss B, Ochsenbauer C, Wahren B, Mhalu F, Sandström E, Biberfeld G, Ferrari G, Polonis VR.

PLoS One. 2015 Apr 14;10(4):e0118486. doi: 10.1371/journal.pone.0118486. eCollection 2015.

9.

Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals.

Hu H, Eller MA, Zafar S, Zhou Y, Gu M, Wei Z, Currier JR, Marovich MA, Kibuuka HN, Bailer RT, Koup RA, Robb ML, Michael NL, Kim JH, Ratto-Kim S.

Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13439-44. doi: 10.1073/pnas.1400446111. Epub 2014 Sep 2.

10.

Designing the epitope flanking regions for optimal generation of CTL epitopes.

Steers NJ, Currier JR, Jobe O, Tovanabutra S, Ratto-Kim S, Marovich MA, Kim JH, Michael NL, Alving CR, Rao M.

Vaccine. 2014 Jun 12;32(28):3509-16. doi: 10.1016/j.vaccine.2014.04.039. Epub 2014 May 2.

PMID:
24795226
11.

Immunology. Immune activation with HIV vaccines.

Fauci AS, Marovich MA, Dieffenbach CW, Hunter E, Buchbinder SP.

Science. 2014 Apr 4;344(6179):49-51. doi: 10.1126/science.1250672. No abstract available.

12.

Mitigation of variation observed in a peripheral blood mononuclear cell (PBMC) based HIV-1 neutralization assay by donor cell pooling.

Wieczorek L, Brown BK, Delsarto Macedo C, Wesberry-Schmierer M, Ngauy V, Rosa Borges A, Michael NL, Marovich MA, Montefiori DC, Polonis VR.

Virology. 2013 Dec;447(1-2):240-8. doi: 10.1016/j.virol.2013.09.014. Epub 2013 Oct 5.

13.

Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.

Nilsson C, Godoy-Ramirez K, Hejdeman B, Bråve A, Gudmundsdotter L, Hallengärd D, Currier JR, Wieczorek L, Hasselrot K, Earl PL, Polonis VR, Marovich MA, Robb ML, Sandström E, Wahren B, Biberfeld G.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):299-311. doi: 10.1089/AID.2013.0149. Epub 2013 Nov 15.

14.

HIV DNA reservoir increases risk for cognitive disorders in cART-naïve patients.

Valcour VG, Ananworanich J, Agsalda M, Sailasuta N, Chalermchai T, Schuetz A, Shikuma C, Liang CY, Jirajariyavej S, Sithinamsuwan P, Tipsuk S, Clifford DB, Paul R, Fletcher JL, Marovich MA, Slike BM, DeGruttola V, Shiramizu B; SEARCH 011 Protocol Team.

PLoS One. 2013 Jul 31;8(7):e70164. doi: 10.1371/journal.pone.0070164. Print 2013. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/18c308ec-1cff-4e93-b4bb-6c9fc3a25a15.

15.

Human FcγRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection.

Boonnak K, Slike BM, Donofrio GC, Marovich MA.

J Immunol. 2013 Jun 1;190(11):5659-65. doi: 10.4049/jimmunol.1203052. Epub 2013 Apr 24.

16.

Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review.

Elizaga ML, Vasan S, Marovich MA, Sato AH, Lawrence DN, Chaitman BR, Frey SE, Keefer MC; MVA Cardiac Safety Working Group.

PLoS One. 2013;8(1):e54407. doi: 10.1371/journal.pone.0054407. Epub 2013 Jan 17.

17.

Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.

Ratto-Kim S, Currier JR, Cox JH, Excler JL, Valencia-Micolta A, Thelian D, Lo V, Sayeed E, Polonis VR, Earl PL, Moss B, Robb ML, Michael NL, Kim JH, Marovich MA.

PLoS One. 2012;7(9):e45840. doi: 10.1371/journal.pone.0045840. Epub 2012 Sep 26.

18.

Single-cell level response of HIV-specific and cytomegalovirus-specific CD4 T cells correlate with viral control in chronic HIV-1 subtype A infection.

Eller MA, Eller LA, Ratto-Kim S, Ouma BJ, Lo V, de Souza M, Guwatudde D, Nails B, Michael NL, Wabwire-Mangen F, Robb ML, Marovich MA, Sandberg JK, Currier JR.

J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):9-18. doi: 10.1097/QAI.0b013e31825c1217.

PMID:
22580564
19.

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.

Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL.

Nature. 2012 Jan 4;482(7383):89-93. doi: 10.1038/nature10766.

20.

Complement-mediated neutralization of dengue virus requires mannose-binding lectin.

Avirutnan P, Hauhart RE, Marovich MA, Garred P, Atkinson JP, Diamond MS.

MBio. 2011 Dec 13;2(6). pii: e00276-11. doi: 10.1128/mBio.00276-11. Print 2011.

21.

Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications.

Currier JR, Robb ML, Michael NL, Marovich MA.

J Transl Med. 2011 Dec 8;9:212. doi: 10.1186/1479-5876-9-212.

22.

A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.

Eller MA, Slike BM, Cox JH, Lesho E, Wang Z, Currier JR, Darden JM, Polonis VR, Vahey MT, Peel S, Robb ML, Michael NL, Marovich MA.

PLoS One. 2011;6(9):e24254. doi: 10.1371/journal.pone.0024254. Epub 2011 Sep 16.

23.

Innate and adaptive immune responses both contribute to pathological CD4 T cell activation in HIV-1 infected Ugandans.

Eller MA, Blom KG, Gonzalez VD, Eller LA, Naluyima P, Laeyendecker O, Quinn TC, Kiwanuka N, Serwadda D, Sewankambo NK, Tasseneetrithep B, Wawer MJ, Gray RH, Marovich MA, Michael NL, de Souza MS, Wabwire-Mangen F, Robb ML, Currier JR, Sandberg JK.

PLoS One. 2011 Apr 19;6(4):e18779. doi: 10.1371/journal.pone.0018779.

24.

Human immunodeficiency virus type 1 infection is associated with increased NK cell polyfunctionality and higher levels of KIR3DL1+ NK cells in ugandans carrying the HLA-B Bw4 motif.

Eller MA, Koehler RN, Kijak GH, Eller LA, Guwatudde D, Marovich MA, Michael NL, de Souza MS, Wabwire-Mangen F, Robb ML, Currier JR, Sandberg JK.

J Virol. 2011 May;85(10):4802-11. doi: 10.1128/JVI.00111-11. Epub 2011 Mar 16.

25.

Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection.

Boonnak K, Dambach KM, Donofrio GC, Tassaneetrithep B, Marovich MA.

J Virol. 2011 Feb;85(4):1671-83. doi: 10.1128/JVI.00220-10. Epub 2010 Dec 1.

26.

Cell type-specific proteasomal processing of HIV-1 Gag-p24 results in an altered epitope repertoire.

Steers NJ, Currier JR, Kijak GH, di Targiani RC, Saxena A, Marovich MA, Kim JH, Michael NL, Alving CR, Rao M.

J Virol. 2011 Feb;85(4):1541-53. doi: 10.1128/JVI.01790-10. Epub 2010 Nov 24.

27.

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.

Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, Earl P, Moss B, Peel S, Slike B, Sriplienchan S, Thongcharoen P, Paris RM, Robb ML, Kim J, Michael NL, Marovich MA.

PLoS One. 2010 Nov 15;5(11):e13983. doi: 10.1371/journal.pone.0013983.

28.

Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes.

Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM.

Lancet Infect Dis. 2010 Oct;10(10):712-22. doi: 10.1016/S1473-3099(10)70166-3. Review.

29.

A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection.

Aronson NE, Wortmann GW, Byrne WR, Howard RS, Bernstein WB, Marovich MA, Polhemus ME, Yoon IK, Hummer KA, Gasser RA Jr, Oster CN, Benson PM.

PLoS Negl Trop Dis. 2010 Mar 9;4(3):e628. doi: 10.1371/journal.pntd.0000628.

30.

Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines.

Earl PL, Cotter C, Moss B, VanCott T, Currier J, Eller LA, McCutchan F, Birx DL, Michael NL, Marovich MA, Robb M, Cox JH.

Vaccine. 2009 Sep 25;27(42):5885-95. doi: 10.1016/j.vaccine.2009.07.039. Epub 2009 Aug 3.

31.

Elevated natural killer cell activity despite altered functional and phenotypic profile in Ugandans with HIV-1 clade A or clade D infection.

Eller MA, Eller LA, Ouma BJ, Thelian D, Gonzalez VD, Guwatudde D, McCutchan FE, Marovich MA, Michael NL, de Souza MS, Wabwire-Mangen F, Robb ML, Currier JR, Sandberg JK.

J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):380-9. doi: 10.1097/QAI.0b013e3181aa256e.

PMID:
19487954
32.

A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy.

Gandhi RT, O'Neill D, Bosch RJ, Chan ES, Bucy RP, Shopis J, Baglyos L, Adams E, Fox L, Purdue L, Marshak A, Flynn T, Masih R, Schock B, Mildvan D, Schlesinger SJ, Marovich MA, Bhardwaj N, Jacobson JM; AIDS Clinical Trials Group A5130 team.

Vaccine. 2009 Oct 9;27(43):6088-94. doi: 10.1016/j.vaccine.2009.05.016. Epub 2009 May 29.

33.

Functional characterization of ex vivo blood myeloid and plasmacytoid dendritic cells after infection with dengue virus.

Sun P, Fernandez S, Marovich MA, Palmer DR, Celluzzi CM, Boonnak K, Liang Z, Subramanian H, Porter KR, Sun W, Burgess TH.

Virology. 2009 Jan 20;383(2):207-15. doi: 10.1016/j.virol.2008.10.022. Epub 2008 Nov 17.

34.

Role of dendritic cells in antibody-dependent enhancement of dengue virus infection.

Boonnak K, Slike BM, Burgess TH, Mason RM, Wu SJ, Sun P, Porter K, Rudiman IF, Yuwono D, Puthavathana P, Marovich MA.

J Virol. 2008 Apr;82(8):3939-51. doi: 10.1128/JVI.02484-07. Epub 2008 Feb 13.

35.

Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessment.

Currier JR, Galley LM, Wenschuh H, Morafo V, Ratto-Kim S, Gray CM, Maboko L, Hoelscher M, Marovich MA, Cox JH.

Clin Vaccine Immunol. 2008 Feb;15(2):267-76. Epub 2007 Dec 12.

36.

An immunocytometric assay based on dengue infection via DC-SIGN permits rapid measurement of anti-dengue neutralizing antibodies.

Martin NC, Pardo J, Simmons M, Tjaden JA, Widjaja S, Marovich MA, Sun W, Porter KR, Burgess TH.

J Virol Methods. 2006 Jun;134(1-2):74-85. Epub 2006 Jan 18.

PMID:
16417930
37.

Differential effects of dengue virus on infected and bystander dendritic cells.

Palmer DR, Sun P, Celluzzi C, Bisbing J, Pang S, Sun W, Marovich MA, Burgess T.

J Virol. 2005 Feb;79(4):2432-9.

38.

Specific antibody production by blood B cells is retained in late stage drug-naïve HIV-infected Africans.

Béniguel L, Bégaud E, Cognasse F, Gabrié P, Mbolidi CD, Marovich MA, Cazorla C, Lucht F, Genin C, Garraud O.

Clin Dev Immunol. 2004 Jun;11(2):121-7.

39.

ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine development.

Marovich MA.

Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S99-104. Review.

PMID:
15285709
40.

Identification of germinal center B cells in blood from HIV-infected drug-naive individuals in Central Africa.

Béniguel L, Bégaud E, Cognasse F, Gabrié P, Mbolidi CD, Sabido O, Marovich MA, DeFontaine C, Frésard A, Lucht F, Genin C, Garraud O.

Clin Dev Immunol. 2004 Mar;11(1):23-7.

41.

DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells.

Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J, Sun W, Eller MA, Pattanapanyasat K, Sarasombath S, Birx DL, Steinman RM, Schlesinger S, Marovich MA.

J Exp Med. 2003 Apr 7;197(7):823-9.

42.

Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells.

Marovich MA, Mascola JR, Eller MA, Louder MK, Caudrelier PA, El-Habib R, Ratto-Kim S, Cox JH, Currier JR, Levine BL, June CH, Bernstein WB, Robb ML, Schuler-Thurner B, Steinman RM, Birx DL, Schlesinger-Frankel S.

J Infect Dis. 2002 Nov 1;186(9):1242-52. Epub 2002 Oct 7.

PMID:
12402193
43.

Leishmaniasis recidivans recurrence after 43 years: a clinical and immunologic report after successful treatment.

Marovich MA, Lira R, Shepard M, Fuchs GH, Kruetzer R, Nutman TB, Neva FA.

Clin Infect Dis. 2001 Oct 1;33(7):1076-9. Epub 2001 Sep 5.

PMID:
11528583
44.

Human skin Langerhans cells are targets of dengue virus infection.

Wu SJ, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, Putvatana R, Louder MK, Filgueira L, Marovich MA, Wong HK, Blauvelt A, Murphy GS, Robb ML, Innes BL, Birx DL, Hayes CG, Frankel SS.

Nat Med. 2000 Jul;6(7):816-20.

PMID:
10888933
45.

IL-12p70 production by Leishmania major-harboring human dendritic cells is a CD40/CD40 ligand-dependent process.

Marovich MA, McDowell MA, Thomas EK, Nutman TB.

J Immunol. 2000 Jun 1;164(11):5858-65.

46.

Aromatic dienoyl tetramic acids. Novel antibacterial agents with activity against anaerobes and staphylococci.

Rosen T, Fernandes PB, Marovich MA, Shen L, Mao J, Pernet AG.

J Med Chem. 1989 May;32(5):1062-9.

PMID:
2709374

Supplemental Content

Loading ...
Support Center